“NeoRAS WT”是指转移性结直肠癌 (mCRC) 一线治疗后 RAS 突变 (MT) 丢失。我们使用血浆循环肿瘤 DNA 的新一代测序来评估 NeoRAS WT mCRC 的发病率和临床病理学特征。参加 GOZILA 研究的 mCRC 患者最初诊断为组织 RAS MT mCRC 并接受后续全身治疗，符合资格。 NeoRAS WT 被定义为血浆中不存在可检测到的 RAS MT，并在所有符合条件的患者（A 组）和血浆中至少检测到一种体细胞改变的亚组（B 组）中进行评估。总共包括 478 名患者。 NeoRAS WT 患病率在 A 组中为 19.0% (91/478)，在 B 组中为 9.8% (42/429)。没有肝脏或淋巴结转移以及除 KRAS 外显子 2 MT 之外的组织 RAS MT 与 NeoRAS WT 的出现显着相关。总体而言，接受抗 EGFR 单克隆抗体 (mAb) 治疗的 NeoRAS WT 患者分别有 1/6 和 2/6 表现出部分缓解和疾病稳定≥6 个月。据观察，NeoRAS WT mCRC 的患病率相当高，基于抗 EGFR mAb 的治疗可能有效。© 2024。作者。

"NeoRAS WT" refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of NeoRAS WT mCRC using next-generation sequencing of plasma circulating tumor DNA. Patients with mCRC enrolled in the GOZILA study initially diagnosed with tissue RAS MT mCRC and received subsequent systemic therapy are eligible. NeoRAS WT is defined as the absence of detectable RAS MT in plasma and assessed in all eligible patients (Group A) and in a subgroup with at least one somatic alteration detected in plasma (Group B). Overall, 478 patients are included. NeoRAS WT prevalence is 19.0% (91/478) in Group A and 9.8% (42/429) in Group B. Absence of liver or lymph node metastasis and tissue RAS MTs other than KRAS exon 2 MTs are significantly associated with NeoRAS WT emergence. Overall, 1/6 and 2/6 patients with NeoRAS WT treated with anti-EGFR monoclonal antibodies (mAbs) show partial response and stable disease for ≥6 months, respectively. NeoRAS WT mCRC is observed at a meaningful prevalence, and anti-EGFR mAb-based therapy may be effective.© 2024. The Author(s).